The GLP-1 class cardiovascular track record Context from the broader GLP-1 receptor agonist class is relevant
All these factors combined can make planning and budgeting for treatment a real challenge
declares speaker fees from TEVA UK, 2020
It is the active pharmaceutical ingredient in Novo Nordisks Ozempic (FDA-approved 2017 for Type 2 diabetes), Wegovy (FDA-approved 2021 for chronic weight management in adults with obesity, and 2024 expanded for cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease), and Rybelsus (oral form, Type 2 diabetes)
However, excessive adiposity, especially in the waist area, translates into an increased risk of various chronic non-communicable diseases, namely cardiovascular disease, type 2 diabetes (DM2), hypertension, dyslipidemia, insulin resistance, sleep apnoea, hepatic steatosis, some forms of cancer, depression, and other comorbidities, ultimately reducing the quality of life of those who suffer from this disease [4,5]